<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945812</url>
  </required_header>
  <id_info>
    <org_study_id>INDV-0909012</org_study_id>
    <nct_id>NCT03945812</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony Stimulating Factor Versus Platelet Rich Plasma and Outcomes of Frozen Embryo Transfer</brief_title>
  <official_title>The Impact of Using Granulocyte Colony Stimulating Factor (G-CSF) Versus Platelet Rich Plasma (PRP) on the Outcomes of Frozen Embryo Transfer; Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wael Elbanna Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Centre, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wael Elbanna Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale behind this current study is to assess the impact of using PRP versus GCSF on&#xD;
      the outcomes of frozen embryo transfer in term of clinical pregnancy rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INTRODUCTION AND STUDY RATIONALE Despite the advancements in the treatment of infertility,&#xD;
      repeated failure of implantation continues as a challenging difficulty.&#xD;
&#xD;
      Embryo implantation is affected by many factors. Many efforts were made to improve the&#xD;
      implantation rate by different methods blastocyst transfer, assisted hatching,&#xD;
      preimplantation genetic screening, hysteroscopy, removal of hydrosalpinges and endometrial&#xD;
      scratch. Furthermore, infertility specialists suggested some empirical methods like the&#xD;
      infusion in the uterine cavity of platelet-rich plasma (PRP) in patients with thin&#xD;
      endometrium which has been shown to be effective in improving the pregnancy rate.&#xD;
&#xD;
      Another factor is granulocyte colony stimulating factor (G-CSF) which has receptors in&#xD;
      endometrial cells and may have a role in implantation. The use of G-CSF in assisted&#xD;
      reproductive technology (ART) has been tried by many research studies either via intrauterine&#xD;
      or systemic administration.&#xD;
&#xD;
      There is only one study compared the impact of PRP and GCSF administration on the pregnancy&#xD;
      rate and on the endometrial thickness with a small sample size.&#xD;
&#xD;
      The rationale behind this current study is to assess the impact of using PRP versus GCSF on&#xD;
      the outcomes of frozen embryo transfer in term of clinical pregnancy rates.&#xD;
&#xD;
      STUDY OBJECTIVES&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      The primary objective of the study is to compare the clinical pregnancy rate determined by&#xD;
      presence of fetal heart beat in transvaginal ultrasound after embryo transfer in all groups.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      To compare the following in the three study arms:&#xD;
&#xD;
        -  Chemical pregnancy determined by positive serum β-HCG, 2 weeks after embryo transfer.&#xD;
&#xD;
        -  Clinical pregnancy rate adjusted by the endometrial thickness (thin versus normal) in&#xD;
           all groups.&#xD;
&#xD;
        -  The midluteal endometrial thickness in all groups (histopathology &amp; TVUS).&#xD;
&#xD;
        -  The number of women who had thin endometrium and reaches endometrial thickness ≥ 7 mm&#xD;
           after using G-CSF or PRP.&#xD;
&#xD;
        -  Implantation rate&#xD;
&#xD;
        -  Miscarriage rate&#xD;
&#xD;
        -  Live-birth rate&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Anticipated">October 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The clinical pregnancy rate</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>The clinical pregnancy rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy rate</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Chemical pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>endometrial thickness in all groups (histopathology &amp; TVUS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Implantation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>With second trimester</time_frame>
    <description>Miscarriage rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live-birth rate</measure>
    <time_frame>1 year</time_frame>
    <description>Live-birth rate</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">390</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Granulocyte Colony Stimulating Factor Arm</arm_group_label>
    <description>Women in this group will receive G-CSF with conventional hormonal therapy:&#xD;
Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma Arm</arm_group_label>
    <description>Women in this group will receive PRP with conventional hormonal therapy:&#xD;
Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <description>Women in this group will receive saline with conventional hormonal therapy:&#xD;
Estradiol valerate 6mg/day from day 2 of menstrual cycle Vaginal sildenafil citrate 25mg / 6 hours Then frozen embryo transfer cycle will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor</intervention_name>
    <description>Filgrastim, Amgen, California, USA 300 mg/1.0 mL</description>
    <arm_group_label>Granulocyte Colony Stimulating Factor Arm</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Platelet Rich Plasma Arm</intervention_name>
    <description>Platelet Rich Plasma Arm</description>
    <arm_group_label>Platelet Rich Plasma Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline 9%</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Saline 9%</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women visiting the center for IVF by frozen embryo transfer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All women aged 20-40 years&#xD;
&#xD;
          -  non-smoker&#xD;
&#xD;
          -  BMI &lt; 30&#xD;
&#xD;
          -  Normal endometrial cavity confirmed by hysteroscopy&#xD;
&#xD;
          -  Visiting the center for IVF by frozen embryo transfer during the period of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of anti-phospholipid syndrome confirmed by serological tests.&#xD;
&#xD;
          -  History of any hematological and immunological disorders&#xD;
&#xD;
          -  History of chromosomal or genetic abnormalities in the patient or in the family&#xD;
&#xD;
          -  Any uterine abnormalities (congenital or acquired)&#xD;
&#xD;
          -  Previous uterine surgeries except caesarean section&#xD;
&#xD;
          -  Hypersensitivity to G-CSF&#xD;
&#xD;
          -  Uncontrolled systemic disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wael SS Elbanna, Consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wael Elbanna Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wael El-Banna Clinic</name>
      <address>
        <city>Maadi</city>
        <state>Cairo</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mehrafza M, Kabodmehri R, Nikpouri Z, Pourseify G, Raoufi A, Eftekhari A, Samadnia S, Hosseini A. Comparing the Impact of Autologous Platelet-rich Plasma and Granulocyte Colony Stimulating Factor on Pregnancy Outcome in Patients with Repeated Implantation Failure. J Reprod Infertil. 2019 Jan-Mar;20(1):35-41.</citation>
    <PMID>30859080</PMID>
  </reference>
  <reference>
    <citation>Coughlan C, Ledger W, Wang Q, Liu F, Demirol A, Gurgan T, Cutting R, Ong K, Sallam H, Li TC. Recurrent implantation failure: definition and management. Reprod Biomed Online. 2014 Jan;28(1):14-38. doi: 10.1016/j.rbmo.2013.08.011. Epub 2013 Sep 14. Review.</citation>
    <PMID>24269084</PMID>
  </reference>
  <reference>
    <citation>Rinehart J. Recurrent implantation failure: definition. J Assist Reprod Genet. 2007 Jul;24(7):284-7. Epub 2007 Aug 3. Review.</citation>
    <PMID>17674185</PMID>
  </reference>
  <reference>
    <citation>Chang Y, Li J, Chen Y, Wei L, Yang X, Shi Y, Liang X. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med. 2015 Jan 15;8(1):1286-90. eCollection 2015.</citation>
    <PMID>25785127</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GCSF</keyword>
  <keyword>PRP</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

